These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 619075)

  • 1. Response to experimental challenge in persons immunized with different rubella vaccines.
    Fogel A; Gerichter CB; Barnea B; Handsher R; Heeger E
    J Pediatr; 1978 Jan; 92(1):26-9. PubMed ID: 619075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity to intranasal challenge with Rubella virus two years after vaccination: comparison of three vaccines.
    Grillner L
    J Infect Dis; 1976 Jun; 133(6):637-41. PubMed ID: 932491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rubella vaccination with "Cendehill" and "RA 27/3". Reinfection of vaccinated and naturally immune persons compared with the infection rate of susceptible persons within a 3-resp. 5-year observation period (author's transl)].
    Thomssen R
    Zentralbl Bakteriol Orig A; 1976 Nov; 236(2-3):163-84. PubMed ID: 1015009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of schoolgirls against rubella. Assessment of serological status and a comparative trial of Wistar RA 27/3 and Cendehill strain live attenuated rubella vaccines in 13-year-old schoolgirls in Dudley.
    Freestone DS; Reynolds GM; McKinnon JA; Prydie J
    Br J Prev Soc Med; 1975 Dec; 29(4):258-61. PubMed ID: 766879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late seroconversion following HPV-77, DE5 rubella virus vaccine.
    Wilkins J
    Am J Obstet Gynecol; 1975 Apr; 121(7):998-1002. PubMed ID: 1115189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of antibody titers after vaccination with rubella virus vaccine ("Cendehill" strain).
    Peetermans J; du Pan RM; Huygelen C
    Dev Biol Stand; 1979; 43():361-5. PubMed ID: 520683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of immunity after rubella vaccination: a long-term study in Switzerland.
    Just M; Just V; Berger R; Burkhardt F; Schilt U
    Rev Infect Dis; 1985; 7 Suppl 1():S91-4. PubMed ID: 4001742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal versus subcutaneous rubella vaccination in schoolgirls.
    Midulla M; Assensio AM; Balducci L; Vanni O; Msstropasqua S
    Dev Biol Stand; 1976; 33():241-8. PubMed ID: 955270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rubella-specific serum and nasopharyngeal antibodies in volunteers with naturally acquired and vaccine-induced immunity after intranasal challenge.
    Harcourt GC; Best JM; Banatvala JE
    J Infect Dis; 1980 Aug; 142(2):145-55. PubMed ID: 7410897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative trial of HPV-77, DE-5 and RA 27-3 live-attenuated rubella vaccines.
    Wallace RB; Isacson P
    Am J Dis Child; 1972 Oct; 124(4):536-8. PubMed ID: 4562789
    [No Abstract]   [Full Text] [Related]  

  • 11. [Rubella vaccination: antibody persistence for 14-17 years and immune status of women without and with a history of vaccination].
    Enders G; Nickerl U
    Immun Infekt; 1988 Apr; 16(2):58-64. PubMed ID: 3391631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal administration of RA 27/3 rubella virus vaccine. A clinical trial in young adults.
    Paradise JE; Nemorofsky D; Huggins GR; Sondheimer SJ; Plotkin SA
    J Adolesc Health Care; 1984 Apr; 5(2):75-8. PubMed ID: 6368506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trials with a live attenuated rubella virus vaccine, Cendehill strain.
    Grant L; Belle EA; Provan G; King SD; Sigel MM
    J Hyg (Lond); 1970 Sep; 68(3):505-10. PubMed ID: 5272349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing and hemagglutination-inhibiting antibodies to rubella virus as indicators of protective immunity in vaccinees and naturally immune individuals.
    Schluederberg A; Horstmann DM; Andiman WA; Randolph MF
    J Infect Dis; 1978 Dec; 138(6):877-83. PubMed ID: 105058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rubella immunization. Persistence of antibody four years after a large-scale field trial.
    Herrmann KL; Halstead SB; Brandling-Bennett AD; Witte JJ; Wiebenga NH; Eddins DL
    JAMA; 1976 May; 235(20):2201-4. PubMed ID: 946844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody titres in women six to eight years after the administration of RA2713 and Cendehill rubella vaccines.
    Macdonald H; Tobin JO; Cradock-Watson JE; Lomax J
    J Hyg (Lond); 1978 Jun; 80(3):337-47. PubMed ID: 649946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Seroimmunity against rubella 5 years after immunisation with Cendehill vaccine (author's transl)].
    Sarateanu DE; Ehrengut W
    Immun Infekt; 1975 Apr; 3(2):51-3. PubMed ID: 1184096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rubella antibody persistence after immunization.
    Herrmann KL; Halstead SB; Wiebenga NH
    JAMA; 1982 Jan; 247(2):193-6. PubMed ID: 7053457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results with the Cendehill rubella vaccine in postpartum women.
    Farquhar JD
    Obstet Gynecol; 1970 Jun; 35(6):841-3. PubMed ID: 5463110
    [No Abstract]   [Full Text] [Related]  

  • 20. Serological response to rubella revaccination.
    Serdula MK; Halstead SB; Wiebenga NH; Herrmann KL
    JAMA; 1984 Apr; 251(15):1974-7. PubMed ID: 6700099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.